Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma Journal Article
| Authors: | Modelevsky, L.; Tizon, R.; Reiss, S. N.; Smith, M.; Garonce, R.; Kaley, T. |
| Article Title: | Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma |
| Abstract: | RESULTS & CONCLUSION: 11 patients received a total of 44 RRIs. Rituximab was dosed at 500 or 750 mg/m2. Premedication included acetaminophen and diphenhydramine. No infusion reactions occurred during any RRI. Two infusions were administered with steroids for neurologic symptoms at baseline (4.5%). Rapid administration of rituximab was safe and feasible for patients with PCNSL and at the higher doses received. AIM: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). PATIENTS & METHODS: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary end point was incidence of infusion reactions. |
| Keywords: | rituximab; primary cns lymphoma; neuro-oncology; rapid infusion |
| Journal Title: | CNS Oncology |
| Volume: | 7 |
| Issue: | 3 |
| ISSN: | 2045-0907 |
| Publisher: | Future Medicine |
| Date Published: | 2018-07-01 |
| Start Page: | CNS19 |
| Language: | English |
| DOI: | 10.2217/cns-2018-0001 |
| PUBMED: | 30221993 |
| PROVIDER: | scopus |
| PMCID: | PMC6200062 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 November 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work